you are here: HomeNewsPharma
pharma
Jump to
1179 Results Found
  • Goldman Sachs Private Equity emerges frontrunner to acquire ChrysCap stake in GVK Biosciences Apr 18, 2021 06:26 PM IST

    Goldman Sachs Private Equity emerges frontrunner to acquire ChrysCap stake in GVK Biosciences

    The CRAMs ( contract research and manufacturing services) segment is fetching rich valuations globally and back home, the segment has seen minority stake sale deals like True North-Anthem Biosciences & TPG-Sai Lifesciences.

  • Q4FY21 preview | Pharma sector likely to see moderate earnings sequentially Apr 14, 2021 10:51 AM IST

    Q4FY21 preview | Pharma sector likely to see moderate earnings sequentially

    Most brokerages anticipate sequential moderation in revenue, EBITDA and PAT for pharma firms for Q4FY21. However, the numbers may still be better on a year-on-year (YoY) basis.

  • Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies? Apr 12, 2021 09:50 PM IST

    Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?

    With the second Covid ‘Wave’ already surpassing the daily highs recorded in the month of September 2020 of about 95000, the demand for vaccines, critical medical equipment like vaccines, oxygen cylinders and ventilators have increased manifold. Watch the video to know what this evolving situation means for Indian Pharma?

  • COVID-19 remains a key trigger for pharma space, analysts pick these 15 stocks for medium term Feb 26, 2021 09:59 AM IST

    COVID-19 remains a key trigger for pharma space, analysts pick these 15 stocks for medium term

    The government's decision to expand the production-linked incentive to the pharma sector will help players who have a strong manufacturing base, say experts.

  • Government extends PLI to more sectors, announces Rs 15,000 crore for pharma, Rs 7350 crore for IT hardware Feb 24, 2021 03:44 PM IST

    Government extends PLI to more sectors, announces Rs 15,000 crore for pharma, Rs 7350 crore for IT hardware

    Centre believes PLI scheme will make India's $ 40 billion pharmaceuticals industry globally competitive and less reliant on imports for high-end patented drugs. The new incentives for domestic manufacture of IT hardware aims to raise domestic value addition to 20% - 25% by 2025 and make India a global hub for Electronics System Design and Manufacturing.

  • Coronavirus Vaccine | How Merck, a vaccine titan, lost the COVID race Feb 11, 2021 01:30 PM IST

    Coronavirus Vaccine | How Merck, a vaccine titan, lost the COVID race

    Merck is now considering a range of options, both in the United States and around the world, mindful that anything it chooses to do would take months to bring to fruition, given the complexity of the manufacturing process

  • Weekly Tactical Pick | Dr Reddy's Laboratories Feb 05, 2021 09:23 AM IST

    Weekly Tactical Pick | Dr Reddy's Laboratories

    Vaccine scope, strong product pipeline to act as tonic for Dr Reddy's Laboratories

  • Budget 2021 | Focus on healthcare but mixed bag for pharma, 9 stocks you can pick from sector Feb 05, 2021 09:21 AM IST

    Budget 2021 | Focus on healthcare but mixed bag for pharma, 9 stocks you can pick from sector

    The sector was in focus in Union Budget 2021. Finance Minister Nirmala Sitharaman in her Budget speech announced an outlay of Rs 2,23,846 crore for health and well being.

  • Laurus Labs: Diversification 2.0 is unfolding Feb 04, 2021 11:45 AM IST

    Laurus Labs: Diversification 2.0 is unfolding

    Laurus lab's earnings growth is likely to maintain a strong momentum even beyond the forecast period on new capacity addition and foray into high growth areas of biotech, CDMO and oncology APIs

  • Lupin: New launches and market share gains are likely to override pricing erosion Feb 03, 2021 09:57 AM IST

    Lupin: New launches and market share gains are likely to override pricing erosion

    New launches in the US, particularly in the inhalation category, and an improving market share are expected to help ride over structural pricing erosion in the near term for Lupin

  • Pharma: Ignore the noise as the core allocation is incremental Feb 01, 2021 07:32 PM IST

    Pharma: Ignore the noise as the core allocation is incremental

    Focus on creating health infrastructure in the Budget 2021 is clearly an incrementally structural move which should indirectly benefit all the domestic oriented companies

  • Dr Reddy’s: Should we look beyond impairments? Jan 31, 2021 10:16 PM IST

    Dr Reddy’s: Should we look beyond impairments?

    Large part of impairment charge taken by Dr Reddy's is explained by the erosion in the value of Nuvaring due to the launch of the additional generic product by Teva

  • Cipla — Large part of COVID opportunity has played out Jan 31, 2021 12:48 PM IST

    Cipla — Large part of COVID opportunity has played out

    In the US market, Albuterol opportunity remains a key lever for Cipla at least till the time Perrigo re-enters although in terms of market share, the drugmaker may be close to maturity

  • Sun Pharma: Sustained traction in speciality to be a re-rating driver Jan 31, 2021 12:42 PM IST

    Sun Pharma: Sustained traction in speciality to be a re-rating driver

    Sun Pharma's India business is expected to gain traction as sub-chronic and acute therapies pick up with the opening up of clinics/OPDs. This is likely to be fully backed by the field force where the expansion has recently been completed

  • China gene firm providing worldwide COVID tests worked with Chinese military Jan 30, 2021 09:46 PM IST

    China gene firm providing worldwide COVID tests worked with Chinese military

    BGI said it uses Tianhe-2 on a commercial basis, as well as other supercomputing platforms, to speed up research.

  • Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher Jan 18, 2021 11:15 PM IST

    Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 10.4 percent Y-o-Y (up 7.6 percent Q-o-Q) to Rs. 2,315.2 crore, according to Prabhudas Lilladher.

  • Glenmark Pharmaceuticals Q3 PAT seen up 27.4% YoY to Rs. 190.8 cr: Prabhudas Lilladher Jan 18, 2021 11:11 PM IST

    Glenmark Pharmaceuticals Q3 PAT seen up 27.4% YoY to Rs. 190.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.5 percent Y-o-Y (down 4.3 percent Q-o-Q) to Rs. 2,638.6 crore, according to Prabhudas Lilladher.

  • Indoco Remedies Q3 PAT seen up 191.2% YoY to Rs. 9.3 cr: Prabhudas Lilladher Jan 18, 2021 11:11 PM IST

    Indoco Remedies Q3 PAT seen up 191.2% YoY to Rs. 9.3 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 17.7 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs. 283.4 crore, according to Prabhudas Lilladher.

  • Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher Jan 18, 2021 11:05 PM IST

    Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 16.1 percent Y-o-Y (down 11.8 percent Q-o-Q) to Rs. 327.9 crore, according to Prabhudas Lilladher.

  • Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher Jan 18, 2021 11:05 PM IST

    Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 12.3 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 4,397.1 crore, according to Prabhudas Lilladher.

  • Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher Jan 18, 2021 10:57 PM IST

    Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 15.3 percent Y-o-Y (down 1.8 percent Q-o-Q) to Rs. 4,234.6 crore, according to Prabhudas Lilladher.

  • Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher Jan 18, 2021 10:52 PM IST

    Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 3,638.1 crore, according to Prabhudas Lilladher.

  • Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher Jan 18, 2021 10:47 PM IST

    Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 15.5 percent Y-o-Y (up 5 percent Q-o-Q) to Rs. 5,799.4 crore, according to Prabhudas Lilladher.

  • Challenges before healthcare and expectations from Budget 2021 Jan 14, 2021 09:49 AM IST

    Challenges before healthcare and expectations from Budget 2021

    According to the National Health Policy, total public health expenditure is expected to hit 2.5% of GDP by 2025 from the current about 1.3%

  • Here's how home-grown pharma startups plan to aid the government’s COVID inoculation drive Jan 13, 2021 02:54 PM IST

    Here's how home-grown pharma startups plan to aid the government’s COVID inoculation drive

    Anticipating that the government will ask the private sector to step in and help with the nationwide vaccination drive, these startups are busy ramping up their infrastructure and training resources to be ready for the inoculation effort

Sections